Article thumbnail

Treatment of Keratoacanthoma with 5% Imiquimod Cream and Review of the Previous Report

By Hye Chan Jeon, Mira Choi, Seung Hwan Paik, Chang Ho Ahn, Hyun Sun Park and Kwang Hyun Cho

Abstract

Keratoacanthoma (KA) is a benign epidermal tumor, characterized by rapid and abundant growth, a tendency toward spontaneous regression and histopathologic similarity to squamous cell carcinoma (SCC). Because KA can be easily misdiagnosed as SCC, surgery is considered the treatment of choice. Recently, regression of KAs following application of 5% imiquimod cream (Aldara®) has been reported. We present 4 cases of KA treated with topical imiquimod, applied 3 to 4 times a week. Obvious improvement was observed after 4 to 6 weeks of application and the lesions were almost cleared leaving scars after 9 to 11 weeks. These results show that topical imiquimod can be an effective option for the conservative management of KA as previously reported. We also suggest that lesions treated with imiquimod cream should be considered for biopsy to judge histopathological remission after 5 to 8 weeks of application to shorten the duration of the treatment

Topics: Case Report
Publisher: Korean Dermatological Association; The Korean Society for Investigative Dermatology
OAI identifier: oai:pubmedcentral.nih.gov:3162267
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A histologic chronology of the clinical course of the keratocarcinoma (so-called keratoacanthoma).
  2. Imiquimod as a possible treatment for keratoacanthoma.
  3. Imiquimod for restoring local immunity in a renal transplant patient with persistent keratoacanthoma.
  4. Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature.
  5. Keratoacanthoma and its clinical variants. Review of the literature and histopathologic analysis of 90 cases.
  6. Keratoacanthoma centrifugum marginatum: response to topical 5-fluorouracil.
  7. Keratoacanthoma observed.
  8. (1998). Keratoacanthoma: a clinically distinct variant of well differentiated squamous cell carcinoma. Adv Anat Pathol
  9. Keratoacanthoma: a clinico-pathologic enigma.
  10. Keratoacanthoma: a tumor in search of a classification.
  11. (2007). Multiple and relapsing keratoacanthomas developing at the edge of the skin grafts site after surgery and after radiotherapy. Dermatol Surg
  12. (1995). Relative amounts of keratin 17 are higher than those of keratin 16 in hair-folliclederived tumors in comparison with nonfollicular epithelial skin tumors.
  13. Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream.
  14. Topical imiquimod for the treatment of keratoacanthomas.
  15. Topical treatment with 5% imiquimod for solitary keratoacanthoma.
  16. Topical treatment with imiquimod may induce regression of facial keratoacanthoma.
  17. (2006). Treatment of keratoacanthoma with 5% imiquimod cream. Ann Dermatol